Search results for "Adverse effect"

showing 10 items of 1065 documents

Stunted root development: A rare dental complication of Stevens-Johnson syndrome

2016

Stevens-Johnson syndrome (SJS) is a severe cutaneous reaction seen rarely in clinical practice. Most often, it occurs as an adverse reaction to certain drugs. When it affects children at a very young age, arrested tooth root development may also be seen. We present a case of a 13 year old boy who suffered from SJ syndrome at the age of 7 years. Incomplete root development was observed in all teeth, as demonstrated by panaromic radiography. Clinical features of this condition and its management are further discussed. We aim to emphasise on the need for dental practitioners to be aware of the potential dental complications of SJS and enable them to recognise and manage the condition at the ea…

medicine.medical_specialtyRoot (linguistics)PediatricsOral Medicine and Pathologybusiness.industryStevens johnsonOdontologíaCase ReportCiencias de la saludSurgeryClinical Practice030207 dermatology & venereal diseases03 medical and health sciencesYoung ageTooth rootstomatognathic diseases0302 clinical medicinemedicineUNESCO::CIENCIAS MÃ DICAS:CIENCIAS MÃ DICAS [UNESCO]businessComplicationAdverse effectGeneral Dentistry030217 neurology & neurosurgeryJournal of Clinical and Experimental Dentistry
researchProduct

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or …

2013

Abstract Background Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that impact patient quality of life (QoL) and reduce survival. Ruxolitinib (RUX), a potent dual JAK1/JAK2 inhibitor, demonstrated superiority in spleen volume and symptom reduction, improved health-related QoL measures, and prolonged survival compared with traditional therapies or placebo in the phase 3 COMFORT studies. Panobinostat (PAN) is a potent oral pan-deacetylase inhibitor (DACi) that inhibits JAK pathway signaling through increased acetylation of the JAK2 protein chaperone HSP90. In phase 1/2 studies in MF, PAN has shown reduction in splenomegaly and JAK2 V617F…

medicine.medical_specialtyRuxolitinibbusiness.industryeducationImmunologyCell BiologyHematologymedicine.diseasePlaceboOff-label useBiochemistryDiscontinuationInternational Prognostic Scoring SystemInternal medicineCohortImmunologymedicineMyelofibrosisbusinessAdverse effecthealth care economics and organizationsmedicine.drugBlood
researchProduct

Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental s…

2016

We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss them mechanistically in the context of expression and other preclinical data.Based on a systematic PubMed search, incidence of overall adverse events, hypertension, dry mouth, and constipation are comparable between mirabegron or solabegron and placebo. Hypertension is the most frequently observed adverse event, but has a similar incidence with mirabegron and placebo. Nevertheless, severe uncontrolled hypertension has become a contraindication for use of mirabegron based on observation o…

medicine.medical_specialtySide effect030232 urology & nephrologyUrologyContext (language use)Adrenergic beta-3 Receptor AgonistsBenzoates03 medical and health sciences0302 clinical medicineSolabegronmedicineAnimalsHumansPharmacology (medical)Adverse effectAniline Compoundsbusiness.industryUrinary Bladder OveractiveGene Expression ProfilingBiphenyl CompoundsGeneral MedicineBiphenyl compoundThiazolesTolerability030220 oncology & carcinogenesisAnesthesiaReceptors Adrenergic beta-3AcetanilidesTolterodinebusinessMirabegronmedicine.drugExpert opinion on drug safety
researchProduct

Fluorescein for resection of high-grade gliomas: A safety study control in a single center and review of the literature

2017

Background: The importance of a complete resection of high-grade gliomas (HGGs) has been highlighted in scientific literature, in order to limit tumor recurrence and above all to improve disease-free survival rates. Several fluorescent biomarkers have been tested to improve intraoperative identification of residual tumor; 5-aminolevulinic acid (5-ALA) and fluorescein sodium (FS) are now starting to play a central role in glioma surgery. We performed a retrospective analysis on 47 patients operated for HGGs. Here we report our preliminary data. Methods: Data of 47 consecutive patients with HGG have been collected in our study (25 males, 22 females; mean age: 60.3 years, range: 27-86 years). …

medicine.medical_specialtySingle CenterResection03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGliomaYELLOW 560 filterMedicinefluorescein sodiumFluoresceinAdverse effectSettore MED/27 - Neurochirurgiabusiness.industrySubtotal ResectionPartial resectionmedicine.diseaseextent of resectionSurgerychemistry5-aminolevulinic acid030220 oncology & carcinogenesisSurgeryNeuro-Oncology: Original ArticleNeurology (clinical)Sodium fluoresceinbusinessNuclear medicinehigh-grade gliomas030217 neurology & neurosurgerySurgical Neurology International
researchProduct

A prospective, randomized pilot study on the safety and efficacy of recombinant human growth and differentiation factor-5 coated onto β-tricalcium ph…

2010

Objectives: The aim of this prospective, randomized clinical trial was to investigate the potential of recombinant human growth and differentiation factor-5 (rhGDF-5) coated onto β-tricalcium phosphate (β-TCP) (rhGDF-5/β-TCP) to support bone formation after sinus lift augmentation. Material and methods: In total, 31 patients participated in this multicenter clinical trial. They required a two-stage unilateral maxillary sinus floor augmentation (residual bone height <5 mm). According to a parallel-group design, the patients were randomized to three treatment groups: (a) augmentation with rhGDF-5/β-TCP and a 3-month healing period, (b) augmentation with rhGDF-5/β-TCP and a 4-month healing per…

medicine.medical_specialtySinus Floor AugmentationMaxillary sinusbusiness.industrySinus liftImplant failureSurgerylaw.inventionClinical trialmedicine.anatomical_structureTrephineRandomized controlled triallawMedicineOral SurgerybusinessAdverse effectClinical Oral Implants Research
researchProduct

Problem solving in psychopharmacotherapy using pharmacokinetic and pharmacogenetic tests

2007

Many problems such as non-response, pharmacokinetic interactions with clinical consequences and adverse effects (pharmacovigilance) may be observed in patients submitted to psychopharmacotherapy. These risks are increased in patients belonging to the category of “special populations”: elderly patients, children and adolescents, patients with a genetic particularity of metabolism or suffering from somatic or psychic comorbidities. Pharmacokinetic and pharmacogenetic tests are useful to solve problems in psychopharmacotherapy and thus improve efficacy and safety. Therapeutic drug monitoring (TDM) is particularly recommended in situations presented above and in patients who are non-compliant. …

medicine.medical_specialtySpecial populationsmedicine.diagnostic_testbusiness.industryTreatment outcomePsychiatry and Mental healthPharmacokineticsTherapeutic drug monitoringPharmacovigilancemedicineIn patientIntensive care medicinebusinessAdverse effectPharmacogeneticsEuropean Psychiatry
researchProduct

Statin intolerance: new data and further options for treatment

2021

Purpose of review Hypercholesterolemia is a major risk factor for cardiovascular diseases. Administration of statins represents the cornerstone of the prevention and treatment of cardiovascular disease, with demonstrated long-term safety and efficacy. This review aims to revisit statin intolerance mechanisms, as well as to discuss new data and therapeutic options. Recent findings Although statins are well tolerated, myopathy and other adverse effects are a challenging problem, being the main reason for poor adherence to treatment and failure in lowering cardiovascular risk. Statin intolerance is the subject of ongoing research, as these drugs are widely used. There are alternative options o…

medicine.medical_specialtyStatinDosemedicine.drug_classHypercholesterolemiaDisease030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeHumansMedicinecardiovascular diseases030212 general & internal medicineRisk factorIntensive care medicineAdverse effectbusiness.industryCholesterolAnticholesteremic Agentsangiopoietin-like 3 protein inhibitors bempedoic acid ezetimibe proprotein convertase subtilisin-kexin type 9 inhibitors statin intolerance Cholesterol LDL Ezetimibe Humans Proprotein Convertase 9 Anticholesteremic Agents Cardiovascular Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypercholesterolemianutritional and metabolic diseasesCholesterol LDLEzetimibeRegimenchemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients. In clinical practice, statin intolerance limits effective…

medicine.medical_specialtyStatinbusiness.industrymedicine.drug_classAlternative medicinePlacebo-controlled studynutritional and metabolic diseasesGeneral MedicineDiseasecomputer.software_genre3. Good healthlaw.inventionRandomized controlled triallawPost-hoc analysismedicinePosition paperlipids (amino acids peptides and proteins)cardiovascular diseasesData miningbusinessIntensive care medicineAdverse effectcomputerArchives of Medical Science
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term ‘statin intolerance’. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 – 15% of patients.In clinical practice, statin intolerance limits effectiv…

medicine.medical_specialtyStatinmedicine.drug_classbusiness.industrynutritional and metabolic diseasesGeneral MedicineDisease3. Good healthClinical PracticemedicineEuropean atherosclerosis societyPhysical therapyEffective treatmentPosition paperlipids (amino acids peptides and proteins)Pharmacology (medical)cardiovascular diseasesStatin therapyIntensive care medicinebusinessAdverse effectExpert Opinion on Drug Safety
researchProduct

Reduced Neck Muscle Strength and Altered Muscle Mechanical Properties in Cervical Dystonia Following Botulinum Neurotoxin Injections : A Prospective …

2016

Cervical dystonia (CD) is a focal dystonia causing involuntary activation of neck and shoulder muscles resulting in abnormal, sustained and painful posturing that may lead to physical disability and social withdrawal [1]. In recent years, botulinum neurotoxin (BoNT) has become the first line therapy for CD [2]. A subjective feeling of neck weakness has been reported as one of the most common localized adverse events of BoNT [2-7]. In clinical practice, this may sometimes be reported as having difficulty keeping the head upright. Although the effects of BoNT have been widely studied [2,5], there have been no prospective studies quantifying changes in maximal isometric neck muscle strength. O…

medicine.medical_specialtyStrength trainingMuscle characteristicsIsometric exerciselcsh:RC346-429lcsh:RC321-57103 medical and health sciences0302 clinical medicinekauladsabilitymedicineCervical dystoniaAdverse effectProspective cohort studylcsh:Neurosciences. Biological psychiatry. Neuropsychiatrylcsh:Neurology. Diseases of the nervous systemDisabilitybusiness.industryMuscle strengthmscle characteristicsSkeletal muscleta3141030229 sport sciencesFocal dystoniamedicine.diseasemscle strengthNeck musclesneckSurgerymedicine.anatomical_structureNeurologyAnesthesiaOriginal ArticleNeurology (clinical)business030217 neurology & neurosurgeryJournal of Movement Disorders
researchProduct